NCT06903130View on ClinicalTrials.gov

Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD)

Not yet recruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

June 1, 2028

Conditions
NMOSD
Interventions
DIAGNOSTIC_TEST

Blood samples for sNfL and sGFAP levels

Blood samples for sNfL and sGFAP levels

Trial Locations (1)

12462

"Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens", Athens

All Listed Sponsors
lead

National and Kapodistrian University of Athens

OTHER

NCT06903130 - Clinical Study to Evaluate the Effects of the Complement C5 Inhibitor Ravulizumab on Serum Neurofilament Light Chain (sNfL) and Glial Fibrillary Acidic Protein (sGFAP) Levels in Patients With Aquaporin-4-Positive (AQP4-Ab+) Neuromyelitis Optica Spectrum Disorder (NMOSD) | Biotech Hunter | Biotech Hunter